Market Cap 5.24B
Revenue (ttm) 47.07M
Net Income (ttm) -223.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475.59%
Debt to Equity Ratio 0.00
Volume 1,005,064
Avg Vol 1,003,322
Day's Range N/A - N/A
Shares Out 71.95M
Stochastic %K 14%
Beta 2.21
Analysts Strong Sell
Price Target $115.64

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 5300
Address:
500 North Beacon Street, 4th Floor, Watertown, United States
ZacksResearch
ZacksResearch Jan. 5 at 8:20 PM
$KYMR surged 82.4% over the past year — what's driving this biotech rocket? 🚀 ✅ Positive phase Ib BroADen study results for KT-621 in eczema ✅ FDA's Fast Track designation boosts prospects 🚀 Outperforming industry, sector & S&P 500 See why current investors might want to hold on here 👉 https://www.zacks.com/stock/news/2812002/kymr-skyrockets-824-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2812002-body-27426&ADID=SYND_STOCKTWITS_TWEET_2_2812002_BODY_27426
0 · Reply
ZacksResearch
ZacksResearch Jan. 5 at 7:20 PM
$KYMR up 82.4% in a year — and biotech bulls are eyeing what comes next 👀 The rally follows strong phase Ib BroADen data for KT-621 and FDA Fast Track designation for atopic dermatitis, a combo that put Kymera firmly on investors’ radar. Is there more upside potential into 2026? Full breakdown here 👉 https://www.zacks.com/stock/news/2812002/kymr-skyrockets-824-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2812002-teaser-27425&ADID=SYND_STOCKTWITS_TWEET_2_2812002_TEASER_27425
0 · Reply
MikeyNJ
MikeyNJ Jan. 5 at 6:38 PM
$KYMR filled most of that big gap up. 23 analysts cover KYMR with average 12 month target of $117. Looks like a pretty good entry point.
1 · Reply
frenulum1
frenulum1 Jan. 2 at 8:40 PM
$KYMR sell the news.. textbook biotech play
0 · Reply
Arcides
Arcides Jan. 2 at 7:09 PM
$KYMR gaps near former all time high levels usually find sellers...not good anymore, very close to fill the gap
0 · Reply
MikeyNJ
MikeyNJ Jan. 2 at 5:39 PM
$KYMR This is typical trading for KYMR. It's still pre-revenue and therefore volatile. Go back over the past few years and look at the chart. In 2023 it rallied from $12 to $43. It then retraced to $29 only to rally back to $50 in 2024. From September 2024 it sold off from $50 back to $22 by March 2025. From there it rallied to the recent high of $103 on the very promising data. The company was also able to take advantage of its stock strength raising $700M in cash at $84/share bringing its cash to approx. $1.6B. Going forward they have adequate cash to advance the pipeline with no need for further dilution. Every analyst has raised price targets since the data with an average target of $117. The volatility is nothing new for KYMR and presents an excellent opportunity to enter. It will hit those analyst targets over time and they will be raised again. Happy New Year!
0 · Reply
frenulum1
frenulum1 Jan. 2 at 3:53 PM
$KYMR CEO wishes all shareholders a Happy New Year.. while unloading a sizable stake
1 · Reply
deedeethegenius
deedeethegenius Dec. 30 at 9:20 PM
0 · Reply
CharacterCharm
CharacterCharm Dec. 27 at 3:33 PM
$KYMR Confidence will depend on whether guidance becomes dependable; customer retention trends will be critical to monitor — discipline in guidance could rebuild trust. The thesis tightens only when delivery matches ambition.
0 · Reply
AlphaMomentumFuse
AlphaMomentumFuse Dec. 27 at 6:51 AM
$KYMR Expectations are resetting toward sustainable results, not one‑off wins. Governance alignment can reduce perceived uncertainty. If milestones become dependable, sentiment could re‑rate quickly. Investors will likely insist on proof before expanding exposure.
0 · Reply
Latest News on KYMR
Kymera Therapeutics Announces Proposed Public Offering

Dec 8, 2025, 4:01 PM EST - 4 weeks ago

Kymera Therapeutics Announces Proposed Public Offering


This Drugmaker's Stock Is Soaring Over 40% Monday

Dec 8, 2025, 3:50 PM EST - 4 weeks ago

This Drugmaker's Stock Is Soaring Over 40% Monday


Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum

Dec 8, 2025, 9:15 AM EST - 4 weeks ago

Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum


The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 5 months ago

The Best Small-Cap Stocks to Buy Now

DNLI WAY


Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Jun 25, 2025, 7:05 AM EDT - 6 months ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update


Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:48 PM EST - 11 months ago

Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript


Kymera: Protein Degradation Could Drive Dupixent-Like Value

Dec 7, 2024, 1:07 AM EST - 1 year ago

Kymera: Protein Degradation Could Drive Dupixent-Like Value


ZacksResearch
ZacksResearch Jan. 5 at 8:20 PM
$KYMR surged 82.4% over the past year — what's driving this biotech rocket? 🚀 ✅ Positive phase Ib BroADen study results for KT-621 in eczema ✅ FDA's Fast Track designation boosts prospects 🚀 Outperforming industry, sector & S&P 500 See why current investors might want to hold on here 👉 https://www.zacks.com/stock/news/2812002/kymr-skyrockets-824-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2812002-body-27426&ADID=SYND_STOCKTWITS_TWEET_2_2812002_BODY_27426
0 · Reply
ZacksResearch
ZacksResearch Jan. 5 at 7:20 PM
$KYMR up 82.4% in a year — and biotech bulls are eyeing what comes next 👀 The rally follows strong phase Ib BroADen data for KT-621 and FDA Fast Track designation for atopic dermatitis, a combo that put Kymera firmly on investors’ radar. Is there more upside potential into 2026? Full breakdown here 👉 https://www.zacks.com/stock/news/2812002/kymr-skyrockets-824-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2812002-teaser-27425&ADID=SYND_STOCKTWITS_TWEET_2_2812002_TEASER_27425
0 · Reply
MikeyNJ
MikeyNJ Jan. 5 at 6:38 PM
$KYMR filled most of that big gap up. 23 analysts cover KYMR with average 12 month target of $117. Looks like a pretty good entry point.
1 · Reply
frenulum1
frenulum1 Jan. 2 at 8:40 PM
$KYMR sell the news.. textbook biotech play
0 · Reply
Arcides
Arcides Jan. 2 at 7:09 PM
$KYMR gaps near former all time high levels usually find sellers...not good anymore, very close to fill the gap
0 · Reply
MikeyNJ
MikeyNJ Jan. 2 at 5:39 PM
$KYMR This is typical trading for KYMR. It's still pre-revenue and therefore volatile. Go back over the past few years and look at the chart. In 2023 it rallied from $12 to $43. It then retraced to $29 only to rally back to $50 in 2024. From September 2024 it sold off from $50 back to $22 by March 2025. From there it rallied to the recent high of $103 on the very promising data. The company was also able to take advantage of its stock strength raising $700M in cash at $84/share bringing its cash to approx. $1.6B. Going forward they have adequate cash to advance the pipeline with no need for further dilution. Every analyst has raised price targets since the data with an average target of $117. The volatility is nothing new for KYMR and presents an excellent opportunity to enter. It will hit those analyst targets over time and they will be raised again. Happy New Year!
0 · Reply
frenulum1
frenulum1 Jan. 2 at 3:53 PM
$KYMR CEO wishes all shareholders a Happy New Year.. while unloading a sizable stake
1 · Reply
deedeethegenius
deedeethegenius Dec. 30 at 9:20 PM
0 · Reply
CharacterCharm
CharacterCharm Dec. 27 at 3:33 PM
$KYMR Confidence will depend on whether guidance becomes dependable; customer retention trends will be critical to monitor — discipline in guidance could rebuild trust. The thesis tightens only when delivery matches ambition.
0 · Reply
AlphaMomentumFuse
AlphaMomentumFuse Dec. 27 at 6:51 AM
$KYMR Expectations are resetting toward sustainable results, not one‑off wins. Governance alignment can reduce perceived uncertainty. If milestones become dependable, sentiment could re‑rate quickly. Investors will likely insist on proof before expanding exposure.
0 · Reply
stu4
stu4 Dec. 26 at 1:46 PM
$KYMR RBC had $AGIO at $85 ..it sits at $29 ..it readjusted its position to $45 !!! Oh yes, take their recommendation at GOSPEL !!!
0 · Reply
stu4
stu4 Dec. 26 at 1:44 PM
$KYMR Nahhhh , insiders are devote employees
2 · Reply
stu4
stu4 Dec. 26 at 1:44 PM
$KYMR oh Jesus ..I thought Riley went under , lol But deployed here for KYMR , lol Next will be Bozo !
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 10:17 PM
$KYMR RSI: 64.46, MACD: 4.9286 Vol: 9.94, MA20: 79.04, MA50: 68.65 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RunnerSignals
RunnerSignals Dec. 23 at 9:01 PM
$NOW $TEM $FLUT $ASMB $KYMR are trending! From AI healthcare to gaming and biotech these top upgrades could be your next big move. see why inside https://stocksrunner.com/news/2025-12-23-stock-upgrades-today-highlight-top-picks
0 · Reply
anachartanalyst
anachartanalyst Dec. 22 at 8:02 PM
$KYMR https://anachart.com/wp-content/uploads/ana_temp/1766433710_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 6:18 PM
B. Riley Securities updates rating for Kymera Therapeutics ( $KYMR ) to Buy, target set at 80 → 117.
0 · Reply
frenulum1
frenulum1 Dec. 17 at 5:50 PM
$KYMR insiders will sell off their gains .. revisit once hype fades off and next phase due out with bigger population size
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 2:01 PM
RBC Capital updates rating for Kymera Therapeutics ( $KYMR ) to Outperform, target set at 70 → 103.
0 · Reply
FALCON765
FALCON765 Dec. 15 at 2:27 AM
$KYMR wow big buyer 172 million dollar ! !
0 · Reply
MaverikIT
MaverikIT Dec. 12 at 9:58 PM
$KYMR - been good 3mth
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 4:50 PM
Fast Track win just lit a fire under $KYMR. The FDA granted Fast Track to KT-621 for moderate to severe atopic dermatitis, giving the stock a boost and pushing its Type 2 pipeline further along. Full breakdown here 👉 https://www.zacks.com/stock/news/2803793/kymeras-eczema-drug-gets-fast-track-designation-in-the-united-states?cid=sm-stocktwits-2-2803793-teaser-24684&ADID=SYND_STOCKTWITS_TWEET_2_2803793_TEASER_24684
0 · Reply